ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

AKARALI expands in the US as consumer demands quality clinically tested Tongkat Ali products

California, United States, 29th Jan 2023 – AKARALI announces its expansion plan into the US market with a wide range clinically-tested Tongkat Ali products that are backed by two decades of research studies and clinical trials.

The herbal dietary supplement market in the US has surpassed USD10 billion for the first time in 2022. 

AKARALI is on track to disrupt the billion-dollar herbal supplements industry as Americans are shifting away from generic Tongkat Ali extract from China, which are mainly sold on Amazon.

CEO of AKARALI USA, Ilan Joffee is leading this expansion plan via Core Supplements LLC, bringing with him decades of marketing experience in the North American market. 

“Our presence in the US is timely as consumers are demanding higher quality Tongkat Ali extract that is clinically tested on humans. We saw a 150% month-on-month growth as AKARALI brings the best quality Tongkat Ali supplements for men. This is an important milestone for us.” Joffee said. 

AKARALI contains the world’s first US-patented standardized Tongkat Ali extract that was jointly formulated by the Massachusetts Institute of Technology (MIT) with more than 26 clinical tests on humans since 2003.

Tongkat Ali first made headlines in America 25 years ago. Recent clinically tested standardized Tongkat Ali extracts are much preferred by consumers due to superior health benefits.

AKARALI Tongkat Ali products are now available on Amazon and produced in a USFDA-inspected facility that is GMP and ISO certified. This is to adhere to the best quality and safety standards.

Clinically-tested Tongkat Ali using standardized hot water extract are reviewed by many medical professionals and health experts as safe.

“We are excited to deliver higher efficacy to our US consumers from quality Tongkat Ali extract due to its faster hormonal-inducing effect on the endocrine system” Joffee said.

“Tongkat Ali (Eurycoma Longifolia) is used for centuries and is one of the few herbal supplements that is backed by more than 300 research studies in the last two decades.”, added Joffee.

Recent studies have shown positive effects in supporting healthy testosterone by up to 582%, stronger immune system, improved sexual libido and men’s fertility, improved mood and general health. 

Tongkat Ali clinical trials showed promising results in addressing low testosterone symptoms, libido and stress for many years. It remains a proven dietary supplement compared to such as Panax Ginseng, Maca or Ashwagandha.

In America, Tongkat Ali has been increasingly popular amongst young adults (both men and women) and used widely as a pre and post workout supplement to increase strength and anaerobic performance. 

“Thanks to increasing clinical trials and research studies, we are confident that potent and clinically tested Tongkat Ali extract is the answer that many Americans are missing at this point” he added.

Media Contact

Organization: akarali

Contact Person: Media Relations

Email: shahid@akarali.com

Phone: +1 (323) 369-3571

Website: http://www.akarali.com

State: California

Country: United States

Release Id: 2901232336

The post AKARALI expands in the US as consumer demands quality clinically tested Tongkat Ali products appeared first on King Newswire.


Information contained on this page is provided by an independent third-party content provider. eTrendystock make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact contact@etrendystock.com

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.